Oncology Research | LifeBridge Health

Cancer Research

Clinical research is required for the development of new drugs, surgical procedures, devices and other therapies designed to address a wide variety of health conditions faced by cancer patients. The LifeBridge Health Department of Oncology Research conducts cutting-edge clinical research and provides the opportunity for patients to participate.

Doctor speaking with a patient

What sets us apart

Our oncologists partner with National Cancer Institute (NCI) oncology cooperative groups and collaborate with major pharmaceutical sponsors to offer impactful clinical trials. With three research locations to choose from your participation in our trial can be convenient and close to your home.

Our clinical trials offer patients:

Nurses dedicated to our clinical trials that support our patients and participants
Access to novel therapies
Access to state-of-the-art therapies
Access to emerging therapies

Who We Are

Important points of contact for anyone wishing to become part of an oncology research trial:

Melissa Loomis, CCRP

Research Program Coordinator

Judy Bosley, RN, BSN, OCN, CCRP

Oncology Research Nurse Manager

Pamela Nickoles, RN, BSN, OCN, CCRP

Oncology Research Nurse

Brittany Layfield, RN, BSN, OCN

Oncology Research Nurse

Active Clinical Trials

Below is a list of active LifeBridge Health adult cancer research trials.
Click the "Department" dropdown menu to filter by specific types of cancer research.

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤

Study # NRG-BR009 Date Opened: 08/31/2023 (All Centers) Principal Investigator: Maitri Kalra, MD

A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)” (NCT 04625647)

Study # S1900E Date Opened: 09/13/2023 (All Centers) Principal Investigator: Vishal Jindal, MD

Gynecologic Cancer

A Phase 2 Open-label Study Evaluating the Efficacy and Safety of luveltamab tazevibulin (STRO-002) in Women with Relapsed Platinum resistant epithelial ovarian cancer (including Fallopian Tube or Primary Peritoneal Cancers) expressing Folate

Study # GOG 3086 / STRO-002-GM3 Date Opened: 09/21/2023 (Pharma) Principal Investigator: Pallavi Kumar, M.D.

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Study # S2206 Date Opened: 11/27/2023 (Sinai & WKRCC) Principal Investigator: Maitri Kalra, MD

A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cel

Study # GSK 213824 Date Opened: 10/14/2022 Principal Investigator: Vishal Jindal, MD

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Study # GS-US-595-6184 Date Opened: 12/12/2022 Principal Investigator: Maitri Kalra, MD

Randomized Phase 3 Clinical Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

Study # EA5221 Date Opened: 07/19/2024 Principal Investigator: Vishal Jindal, MD

The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and t

Study # A011801 Date Opened: 05/06/2023 (All Centers) Principal Investigator: Maitri Kalra, MD

Gynecologic Cancer

Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR?-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube,

Study # IMGN853-0421 Date Opened: 02/28/2023 (Sinai) Principal Investigator: Pallavi Kumar, M.D.

Gastrointestinal Cancer

NRG GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

Study # NRG GI008 Date Opened: 03/21/2023 (All Centers) Principal Investigator: Pallavi Kumar, M.D.

Gynecologic Cancer

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Ca

Study # NRG GY026 Date Opened: 01/07/2023 (All Centers) Principal Investigator: Pallavi Kumar, M.D.

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Study # NCT#02194738 Date Opened: 01/01/2016 (All Centers) Principal Investigator: Qiwei Gai

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (NCT#04267848)

Study # A081801 Date Opened: 08/17/2020 (All Centers) Principal Investigator: Qiwei Gai

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) (NCT#3851445)

Study # LUNGMAP Date Opened: 04/09/2019 (All Centers) Principal Investigator: Qiwei Gai

Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung

Study # S2302 Date Opened: 04/12/2023 (All Centers) Principal Investigator: Mayer Gorbaty

Supportive Care

The Caris Biorepository Research Protocol

Study # TCBIO-001-0710 Date Opened: 12/01/2022 (All Centers) Principal Investigator: Pallavi Kumar, M.D.

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)”

Study # S1827 Date Opened: 08/18/2023 (Khalert Only) Principal Investigator: David Perry, M.D.

A191901: OPTIMIZING ENDOCRINE THERAPY THROUGH MOTIVATIONAL INTERVIEWING AND TEXT INTERVENTIONS

Study # A191901 Date Opened: 02/15/2021 Principal Investigator: Qiwei Gai